Investing.com -- The biotechnology sector continues to offer compelling investment opportunities in 2026, with several companies poised for significant growth according to Bank of America analysts.
Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results